Associate Professor @UZH_en @Unispital_USZ @CCCZ_USZ studying the pathogenesis of cancer with a particular focus on TP53-mutant myeloid (pre-)malignancies

Joined May 2019
31 Photos and videos
Boettcher Lab retweeted
At #EHA2026, the #HemaSphereAwards recognize authors of influential hematology publications. Congratulations to Ana Luísa Pereira, Serena Galli, and César Nombela-Arrieta for their study on bone marrow niches for hematopoietic stem cells👉onlinelibrary.wiley.com/doi/…
1
1
14
504
Boettcher Lab retweeted
Excited to share our latest work. Applying advanced single-molecule and single-cell DNA sequencing methods, we uncover an extraordinary landscape of somatic mutations in immune checkpoint genes in autoimmune lymphocytes. [1/n] rdcu.be/fdqbr

7
67
194
32,358
Boettcher Lab retweeted
Ercc6l2 deficiency leads to replication stress, p53 pathway activation, and decreased Runx1 and Gata1 expression resulting in BMF. Read the plenary paper in Blood: ow.ly/nZ5l50YGL8b #plenarypaper #bloodjournal #p53
8
26
1,951
I’m also very delighted to share the news that I have been promoted to #AssociateProfessor. @UZH_en @Unispital_USZ @CCCZ_USZ 🍾🥂🎉
2
16
682
Boettcher Lab retweeted
Welcome to #ESHAL2026! Stay tuned! ESH Young Scientific Reporters @DKotsos & @TanMeg9595 will provide regular updates on the conference! February 27-March 1, 2026 Chairs: @DombretHerve, Christoph Röllig, @DrWendyStock #ESHCONFERENCES #leusm @Hemasphere_EHA
3
5
381
Getting started for #ESHAL2026 @ESHaematology.
3
165
Boettcher Lab retweeted
Now online in @CD_AACR: Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators - by @FerranFeceCruz, @AndreasVarkaris, @aparna1024, Ryan Corcoran, and colleagues doi.org/10.1158/2159-8290.CD… @MassGenBrigham @MGBResearchNews @harvardmed
Now online: Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators doi.org/10.1158/2159-8290.CD…
3
7
4,379
1/🔥 New paper from our lab! #TP53-mutant clonal hematopoiesis (#CH) greatly increases risk for therapy-related #AML/MDS - but why? We set out to dissect how mono- vs. biallelic #TP53 mutations drive leukemic evolution. nature.com/articles/s41375-0…
4
15
70
8,979
7/🎯 Take-home message: Biallelic #TP53 inactivation is the key driver of leukemic transformation from CH → t-AML/MDS. Non-mutational p53 inactivation matters (as recently shown #PMID: 40315418) Findings support biallelic #TP53-mutant AML/MDS as a distinct biological entity.
1
3
262
8/🍾🎉 Congratulations to #JonasFullin and the entire team, and many thanks to all collaborators! 📄 Read the full paper here: “The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis” nature.com/articles/s41375-0…
1
4
226